Search Results for: "Clinic Roundup"
-
Clinic Roundup
Top-line results are expected around the end of 2008BioWorld Today | Thursday, May 17, 2007 -
Clinic Roundup
AlphaRx Inc., of Markham, Ontario, and Proprius Pharmaceuticals Inc., of San Diego, said top-line results from an exploratory Phase II trial of Indaflex 2.5 percent topical indomethacin cream in osteoarthritis of the knee did not meet the primary endpointsBioWorld Today | Wednesday, May 16, 2007 -
Clinic Roundup
The firm expects to present top-line, 52-week results later this yearBioWorld Today | Thursday, May 3, 2007 -
Clinic Roundup
Anesiva Inc., of South San Francisco, said top-line Phase II data of 4975 in postsurgical pain associated with total knee replacement demonstrated a significant reduction in pain on first ambulation on first day postsurgery and reduction in "pain right now" and "worst pain in past 24 hours" on Brief Pain Inventory at two weeks postsurgery...DeCODE genetics Inc., of Reykjavik, Iceland, reported positive, top-line Phase I results showing that DG051 reduced leukotriene B4 production in a doseBioWorld Today | Wednesday, May 2, 2007 -
Clinic Roundup
Cobalis Corp., of Irvine, Calif., said its independent contract research organization will need more time to combine Cobalis' three locked databases into a single database before unblinding and conducting the statistical analysis required to generate top-line results for Cobalis' twin pivotal Phase III Clinical Trials of PreHistin in seasonal allergic rhinitis...The company anticipates reporting its top-line results later in MayBioWorld Today | Tuesday, May 1, 2007 -
Clinic Roundup
Opexa Therapeutics Inc., of The Woodlands, Texas, disclosed positive top-line data from an open-label Phase I/II dose-escalation trial of the T-cell vaccine, Tovaxin, for multiple sclerosisBioWorld Today | Wednesday, April 4, 2007 -
Clinic Roundup
Top-line efficacy and genetic biomarkers results are expected in the third quarterBioWorld Today | Tuesday, March 27, 2007 -
Clinic Roundup
CeNeRx BioPharma Inc., of Research Triangle Park, N.C., said top-line results from a Phase I trial of Tyrima, its lead candidate for depression and anxiety, showed the drug to be safe and well toleratedBioWorld Today | Wednesday, March 14, 2007 -
Clinic Roundup
Alkermes expects to provide top-line results from the study in the first half of 2007...The trials, which are being conducted under a special protocol assessment from the FDA, are expected to conclude in the fourth quarter, with top-line results available by the end of the yearBioWorld Today | Wednesday, March 7, 2007 -
Clinic Roundup
InSite Vision Inc., of Alameda, Calif., said top-line results from its Phase I study of AzaSite Plus (ISV-502), a combination antibiotic/corticosteroid product formulated in DuraSite, showed that the product was well tolerated, with no serious adverse events reportedBioWorld Today | Wednesday, February 14, 2007 -
Clinic Roundup
Zelos Therapeutics Inc., of West Conshohocken, Pa., said top-line results from a Phase II study showed that Ostabolin-C, a parathyroid hormone analogue, met its primary objective by demonstrating a statistically significant, dose response increase in mean lumbar spine bone mineral density that reached 5.2 percent at the highest dose testedBioWorld Today | Friday, February 9, 2007 -
Clinic Roundup
Following data validation and analysis, the company expects to report top-line trial results in mid-second quarter of this yearBioWorld Today | Tuesday, February 6, 2007 -
Clinic Roundup
Neurochem said it plans to release the top-line results of the trial in the spring, as previously announcedBioWorld Today | Friday, February 2, 2007 -
Clinic Roundup
Clinical investigators in the study have commenced patient dosing, and top-line results are expected in the middle of 2007BioWorld Today | Thursday, February 1, 2007 -
Clinic Roundup
Inflazyme Pharmaceuticals Ltd., of Vancouver, British Columbia, announced that top-line data from a Phase IIb trial of asthma drug IPL512,602 demonstrated no statistically significant differences between drug and placebo groups due to a high response rate in both groupsBioWorld Today | Wednesday, January 31, 2007 -
Clinic Roundup
The company also is finishing up a 40-patient Phase II study of Lymphoseek in breast cancer and melanoma and expects to report top-line data later this quarterBioWorld Today | Thursday, January 18, 2007 -
Clinic Roundup
AtheroGenics Inc., of Atlanta, refined its guidance on its top-line results from the ARISE (Aggressive Reduction of Inflammation Stops Events) Phase III trial, stating that data would be available on AGI-1067 no sooner than late in the first quarterBioWorld Today | Wednesday, January 10, 2007 -
Clinic Roundup
Aerovance Inc., of Berkeley, Calif., reported top-line results from a Phase IIa trial in asthma patients, showing that twice-daily use of inhaled Aerovant (IL-4 and IL-13 antagonist) reduced the severity of late asthmatic response by a statistically significant 72 percent compared to baseline, meeting the trial's primary endpointBioWorld Today | Thursday, January 4, 2007 -
Clinic Roundup
Threshold Pharmaceuticals Inc., of Redwood City, Calif., said top-line results from its Phase II trial of glufosfamide in combination with gemcitabine as a first-line treatment of pancreatic cancer showed that 21 percent (6 patients) of the 28 patients evaluated had a partial response (including one unconfirmed partial response) and 36 percent (10 patients) had stable diseaseBioWorld Today | Friday, December 29, 2006 -
Clinic Roundup
UCB SA, of Brussels, Belgium, reported positive top-line results from two Phase III studies of Cimzia (certolizumab pegol), a Fab fragment anti-TNF therapy for rheumatoid arthritisBioWorld Today | Tuesday, December 26, 2006
Category
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.